Literature DB >> 27149919

Diagnostic delay in narcolepsy type 1: combining the patients' and the doctors' perspectives.

Raquel N Taddei1, Esther Werth1, Rositsa Poryazova1, Christian R Baumann1, Philipp O Valko1.   

Abstract

Narcolepsy type 1 is a neurological disorder characterized by a unique syndrome, including the pathognomonic symptom of cataplexy. The diagnosis can be confirmed by objective measures, such as typical findings in the multiple sleep latency test, reduced or undetectable levels of orexin (hypocretin) in the cerebrospinal fluid, and linkage to a specific HLA haplotype. Nevertheless, the mean time that elapses from symptom onset to the correct diagnosis ranges between 10 and 20 years, and the causes and correlates of this delay are poorly understood. Diagnostic delay was assessed on 52 well-defined patients with narcolepsy type 1, evaluating clinical, electrophysiological and neurochemical parameters and the results of a 41-item questionnaire developed to obtain the patients' perspective on various aspects of the diagnostic process. The mean time gap between disease onset and first medical consultation was 3.2 ± 5.1 years; the mean diagnostic delay was 8.9 ± 11.0 years. Prior to correct diagnosis, patients received a wide variety of misdiagnoses. The self-ratings of the patients revealed that the undiagnosed symptoms caused high levels of anxiety and unjustified criticism by family, friends and employers. Multiple regression analysis identified higher cerebrospinal fluid orexin levels (β = 0.311, P = 0.01), and a longer interval between the onset of excessive daytime sleepiness and cataplexy (β = 0.368, P = 0.002) as independent associates of longer diagnostic delay. The diagnostic delay decreased over the last decades (β = -0.672, P < 0.001). In conclusion, delayed diagnosis of narcolepsy type 1 is very common, associated with many adverse consequences, and requires educational efforts to improve awareness on narcolepsy among healthcare providers and the general population.
© 2016 European Sleep Research Society.

Entities:  

Keywords:  central hypersomnia; diagnostic process; sleep-wake disorder

Mesh:

Substances:

Year:  2016        PMID: 27149919     DOI: 10.1111/jsr.12420

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  12 in total

1.  Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy.

Authors:  Kiran Maski; Erin Steinhart; David Williams; Thomas Scammell; Julie Flygare; Kimberly McCleary; Monica Gow
Journal:  J Clin Sleep Med       Date:  2017-03-15       Impact factor: 4.062

2.  Giving a voice to cataplectic experience: recollections from patients with narcolepsy type 1.

Authors:  Christian Franceschini; Chiara Fante; Maria Claudia Folli; Maria Filosa; Fabio Pizza; Elena Antelmi; Francesca Ingravallo; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2020-04-15       Impact factor: 4.062

Review 3.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

4.  Medical specialty visits and diagnoses received by Saudi patients prior to a diagnosis of narcolepsy.

Authors:  Aljohara S Almeneessier; Sara Al-Jebrin; Reem Labani; Hussain Alkaff; Omar Al-Rahbeeni; Musab Alageel; Awad Olaish; Ahmed S BaHammam
Journal:  Sleep Breath       Date:  2019-02-28       Impact factor: 2.816

5.  Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study.

Authors:  Ulf Kallweit; Georg Nilius; Daniel Trümper; Tobias Vogelmann; Tino Schubert
Journal:  J Clin Sleep Med       Date:  2022-06-01       Impact factor: 4.324

6.  Comorbidities in a community sample of narcolepsy.

Authors:  Alexander Cohen; Jay Mandrekar; Erik K St Louis; Michael H Silber; Suresh Kotagal
Journal:  Sleep Med       Date:  2017-11-21       Impact factor: 3.492

7.  Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States.

Authors:  Kathleen F Villa; Nancy L Reaven; Susan E Funk; Karen McGaughey; Jed Black
Journal:  Am Health Drug Benefits       Date:  2018-05

8.  Narcolepsy type 1 features across the life span: age impact on clinical and polysomnographic phenotype.

Authors:  Althea Lividini; Fabio Pizza; Marco Filardi; Stefano Vandi; Francesca Ingravallo; Elena Antelmi; Oliviero Bruni; Filomena Irene Ilaria Cosentino; Raffaele Ferri; Biancamaria Guarnieri; Sara Marelli; Luigi Ferini-Strambi; Andrea Romigi; Enrica Bonanni; Michelangelo Maestri; Michele Terzaghi; Raffaele Manni; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2021-07-01       Impact factor: 4.324

9.  Status epilepticus in the Canadian Arctic: A public health imperative hidden in plain sight.

Authors:  Marcus C Ng; Milena Pavlova
Journal:  Epilepsia Open       Date:  2021-09-18

10.  Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study.

Authors:  Caitlin N Dodd; Maria de Ridder; Wan-Ting Huang; Daniel Weibel; Maria Giner-Soriano; Silvia Perez-Vilar; Javier Diez-Domingo; Lawrence W Svenson; Salahddin M Mahmud; Bruce Carleton; Monika Naus; Jeffrey C Kwong; Brian J Murray; Lisen Arnheim-Dahlstrom; Lars Pedersen; Rosa Morros; Francisco Javier Puertas; Steven Black; Miriam Sturkenboom
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.